Our laboratory research work focuses on treatment planning and light dosimetry for interstitial and intraoperative PDT. We aim to improve the quality of life and survival for patients with locally advanced head neck cancer or lung cancer, who failed to respond to standard therapies or have no effective current treatments. We work in close collaboration with physicians to translate the technologies developed in the laboratory into the clinic. The laboratory also supports clinical studies and off label use of PDT in the treatment of patients with head and neck and lung cancer.
Project Title: Integrated Image-Guided Dosimetry and Treatment Planning for Photodynamic Therapy
Source and ID: R01 CA193610 NCI/NIH
Project Period: 12/1/15-11/30/20
Role: Principal investigator (PI)
Major Goals: The objective of this study is to use the power of our integrated dosimetry system to study and define optimal fluence rate and fluence for interstitial photodynamic therapy in locally advanced head and neck cancer.
Project Title: Mechanisms and Strategies for Optimization
Source and ID: P01 CA55791 NCI/NIH
Project Period: 6/16/15-5/31/19
Role: Project Co-Leader
Description: The major goal of this program project is to demonstrate that PDT with HPPH results in long-term tumor responses that compare, or better than, the current standards of care. In the scientific part of this project, we will research how PDT can be improved by enhancing cancer cells’ retention of new photosensitizing drugs, based on tumor-specific characteristics, and investigate how PDT impacts patient antitumor immunity.
Project Title: Interstitial Intensity Modulated Photodynamic Therapy (i-IMPDT)
Source and ID: R43CA213654, Simphotek Inc NIH/NCI
Project Period: 06/1/2017 – 11/30/2017
Role: Subcontract PI
Description: The major goal of this project is to develop a commercial prototype of software and hardware that will include computational tool for light transport and photokinetics for interstitial PDT.
1. Shafirstein G, Battoo A, Harris KE, Baumann H, Gollnick SO, Lindenmann J, Nwogu CE. Photodynamic Therapy of Non-Small Cell Lung Cancer: Narrative Review and Future Directions. Ann Am Thorac Soc. 2016, 13, 265-275. PMID: 26646726; PMCID: PMC5015713
2. Rigual N, Shafirstein G, Cooper MT, Baumann H, Bellnier DA, Sunar U, Tracy EC, Rohrbach DJ, Wilding G, Tan W, Sullivan M, Merzianu M, Henderson BW. Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity. Clin Cancer Res. 2013 Dec 1;19(23):6605-13. PubMed PMID: 24088736; PubMed Central PMCID: PMC3911775.
3. Shafirstein G, Rigual NR, Arshad H, Cooper MT, Bellnier DA, Wilding G, Tan W, Merzianu M, Henderson BW. Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study. Head Neck. 2015 Jan 10;PubMed PMID: 25580824; PubMed Central PMCID: PMC4499022.
4. Oakley E, Wrazen B, Bellnier DA, Syed Y, Arshad H, Shafirstein G. A new finite element approach for near real-time simulation of light propagation in locally advanced head and neck tumors. Lasers Surg Med. 2015 Jan;47(1):60-7. PubMed PMID: 25559426; PubMed Central PMCID: PMC4304874.
5. Oakley,E.; Bellnier, D.A.; Hutson, A.; Wrazen, B.; Arshad, H.; Quon, H.; Shafirstein, G. Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 2017, 49, 599-608. PMCID:PMC5513772